Esperion Therapeutics ESPR Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's payments of stock issuance costs?
- Esperion Therapeutics (ESPR) reported payments of stock issuance costs of $0 in Q1 2026.
- How has Esperion Therapeutics's payments of stock issuance costs changed year-over-year?
- Esperion Therapeutics's payments of stock issuance costs decreased by 100.0% year-over-year, from $7.5M to $0.
- What does payments of stock issuance costs mean?
- This metric captures the direct cash outflows incurred by the company to facilitate the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. These costs are deducted from the gross proceeds of stock offerings to determine the net capital raised. Monitoring these expenses is essential for evaluating the efficiency of the company's capital-raising activities and the impact of transaction costs on net liquidity.